Why did Dr. Reddy's Laboratories (DRREDDY) stock move recently?

On 7/9/2026, Dr. Reddy's Laboratories moved -5.9% — Dr Reddy's shares fell ~6% after the company delayed commercial supplies of its semaglutide product due to a quality issue with the active pharmaceutical ingredient (API) in certain batches. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Dr. Reddy's Laboratories (DRREDDY) overvalued or fairly valued?

MarketChacha shows Dr. Reddy's Laboratories's valuation in context — a forward P/E of about 19.3, a price-to-book of about 2.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Dr. Reddy's Laboratories's revenue?

Dr. Reddy's Laboratories reported revenue of ₹20,533 Cr for FY2026, with net profit of ₹3,220 Cr, per official filings.

What is the share price of Dr. Reddy's Laboratories (DRREDDY)?

Dr. Reddy's Laboratories last traded at ₹1,148.10 (+0.3% on the day), as of 7/31/2026 — a delayed quote shown for education, not investment advice.

Dr. Reddy's Laboratories

DRREDDY · NSE · Pharma · India

Snapshot

TickerDRREDDY

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees27,527

HeadquartersHyderabad, India

Websitewww.drreddys.com

Filings tracked14

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Who owns it

Promoters29.8%
Institutions52.3%
Public & other17.9%

218 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 2.6 points over the period — profitability is trending down.

Net margin trend18.3% → 15.7%

Margin has compressed by about 2.6 points over the period — profitability is trending down.

Growth qualityrev -6% · PAT -11%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (BSE (official results filing)). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹8,985 Cr · EPS 11.79

Est. earnings growth -20.2%

Next fiscal year

Rev ₹39,278 Cr · EPS 59.54

Est. earnings growth +33.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Annual

Quarterly · last 5

Revenue (FY2026)

₹20,533 Cr

Net margin

15.7%

Revenue CAGR (3y)

-5.9%

Profit CAGR (3y)

-10.6%

EPS (FY2026)

38.68

Net profit (FY2026)

₹3,220 Cr

Ask MarketChacha about DRREDDY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 9, 2026
Dr Reddy's shares fell ~6% after the company delayed commercial supplies of its semaglutide product due to a quality issue with the active pharmaceutical ingredient (API) in certain batches.
source 1 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about DRREDDY

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹20,533 Cr	₹3,220 Cr	38.68	15.7%
FY2025	₹32,554 Cr	₹5,654 Cr	—	17.4%
FY2024	₹27,916 Cr	₹5,578 Cr	—	20.0%
FY2023	₹24,670 Cr	₹4,507 Cr	—	18.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	₹8,071 Cr	₹444 Cr	—	5.5%
2026Q1	₹7,516 Cr	₹220 Cr	—	2.9%
2025Q4	₹4,283 Cr	₹91 Cr	1.09	2.1%
2025Q3	₹8,805 Cr	₹1,437 Cr	—	16.3%
2025Q2	₹8,545 Cr	₹1,418 Cr	—	16.6%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

Filings & announcements

2026

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Press Release
BSE8/1/2026
Dr Reddys Laboratories Ltd - 500124 - Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE7/29/2026
Dr Reddys Laboratories Ltd - 500124 - Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE7/29/2026
Dr Reddys Laboratories Ltd - 500124 - Clarification sought from Dr Reddys Laboratories Ltd
The Exchange has sought clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.business-standard.com dated July 28, 2026, (Link:https://www.business-standard.com/companies/news/dr-reddys-first-in-class-gonorrhoea-drug-gets-thailand-approval-after-us-nod-126072700632_1.html) ....
BSE7/28/2026material
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Change in Management
Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015
BSE7/23/2026
Dr Reddys Laboratories Ltd - 500124 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s Report
BSE7/23/2026material
Dr Reddys Laboratories Ltd - 500124 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of 42nd Annual General Meeting
BSE7/23/2026material
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE7/9/2026
Dr Reddys Laboratories Ltd - 500124 - Letter To Shareholders In Relation To Integrated Annual Report Of The Company For FY 2025-26
Please find enclosed letter to shareholder in relation to Integrated Annual Report of the Company for FY 2025-26
BSE6/30/2026
Dr Reddys Laboratories Ltd - 500124 - Business Responsibility and Sustainability Reporting (BRSR)
Please find enclosed Business Responsibility and Sustainability Report FY 2026
BSE6/30/2026
Dr Reddys Laboratories Ltd - 500124 - Notice Of The 42Nd Annual General Meeting Scheduled On July 23, 2026.
Please find enclosed Notice of the 42nd Annual General Meeting of the Company.
BSE6/30/2026material
Dr Reddys Laboratories Ltd - 500124 - Reg. 34 (1) Annual Report.
Please find enclosed Integrated Annual Report FY 2025-26
BSE6/30/2026
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE6/25/2026
Dr Reddys Laboratories Ltd - 500124 - Board Meeting Intimation for Considering The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ending On June 30, 2026
Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2026 ,inter alia, to consider and approve the Un-audited Standalone ....
BSE6/22/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.